Exenatide (glucagon-like-peptide-1 analogue) was authorized for marketing in the European Union in November 2006 and was approved by FDA in April 2005.To improve compliance, exenatide double-walled microspheres (DWMS) were prepared using O1/O2/W method, and physicochemical characterization, in vitro release and degradation of DWMS were evaluated.